Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | TACR3 | P29371 | 2/20 | 0.37 |
| ▸ | DHODH | Q02127 | 3/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17035150 | 0.91 | NUDT1 (0.40) | TOP1ADORA2AMAPTDHODH | |
| SCHEMBL20967905 | 0.90 | TOP1 (0.44) | TOP1ADORA2ASCN9AMAPK10MAPK14 | |
| SCHEMBL20967918 | 0.89 | TOP1 (0.47) | TOP1ADORA2ASCN9AMAPK10MAPK14 | |
| SCHEMBL20249897 | 0.89 | NUDT1 (0.40) | ADORA2AMAPTDHODH | |
| SCHEMBL20967907 | 0.87 | TOP1 (0.47) | TOP1ADORA2ASCN9AMAPK10MAPK14 | |
| SCHEMBL18200499 | 0.85 | DHODH (0.37) | TOP1ADORA2AMAPK10MAPTDHODH | |
| SCHEMBL20967833 | 0.85 | TOP1 (0.44) | TOP1ADORA2ASCN9AMAPK10MAPK14 | |
| SCHEMBL20967906 | 0.82 | TOP1 (0.41) | TOP1ADORA2ASCN9AMAPK10MAPK14 | |
| SCHEMBL20967832 | 0.81 | TOP1 (0.44) | TOP1ADORA2ASCN9AMAPK10MAPK14 | |
| SCHEMBL17034974 | 0.79 | DHODH (0.41) | TOP1ADORA2ADHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10998503-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-05-04 | — | — | US | disclosed |
| US-20190131544-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10998503-B2 | Condensed cyclic compound and organic light-emitting device including the same | CRY1, CRY2, LAGE3 | TOP1 1413/4885ADORA2A 4437/4885SCN9A 1383/4885 |
| US-20190131544-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, LAGE3 | TOP1 1413/4885ADORA2A 4437/4885SCN9A 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.